View in Chinese
James Huang

James Huang

James Huang joined Kleiner Perkins Caufield & Byers China as a managing partner in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. James has made more than 15 investments in China since 2007.

Before coming to KPCB China, James was a managing partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. While at Vivo, James led numerous investments in China. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson).

James is Chairman of Board at Kindstar Global, JHL Biotech and Director at GenScript, ChiralQuest, Zenesis, CVie Therapeutics, EntreMed, XW Laboratory and Omni Pharmaceuticals.

James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley. He was born in Taipei, Taiwan.

Kleiner Perkins Caufield & Byers is a venture capital firm with over 40 years of experience helping entrepreneurs deliver world changing ideas to market.

KPCB Shanghai Office I

Room 2903. No. 3 Building, Fortune Seaview Garden Lane 258, Pu Ming RoadShanghai 200120 PRC

Office +86 21 3383 0688 | Fax +86 21 3383 0699 | Email [email protected]

KPCB Shanghai Office II

No. 6, Lane 1350 Middle Fu Xing RoadXuhui District, Shanghai 200031 PRC

Office +86 21 6025 2100 | Fax +86 21 6025 2110 | Email [email protected]